

25<sup>th</sup> January 2024

- |   |   |
|---|---|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers<br/>Dalal Street,<br/>Mumbai 400 001<br/><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex<br/>Bandra (East), Mumbai - 400 051<br/><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II<br/>L-1840 Luxembourg</p>                             |   |

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby notify the following updates:

- i) Based on the recommendation of the Nomination and Remuneration Committee, the Board, in its meeting held today i.e., on 25<sup>th</sup> January, 2024, has approved the appointment of Dr. Balram Bhargava (DIN: 10479707) as an additional and independent director of the Company for a period of 5 years with effect from 1<sup>st</sup> April 2024 to 31<sup>st</sup> March 2029 (both days inclusive). The appointment will be subject to the approval of the shareholders.
- ii) Vide letter dt. 25<sup>th</sup> January, 2024, effective close of business hours of 31<sup>st</sup> March, 2024, Ms. Samina Hamied (DIN: 00027923) has decided to step down from the position of Executive Vice Chairperson of the Company, while continuing as a non-executive director liable to retire by rotation. The Board has accepted the above letter in its meeting held today i.e., on 25<sup>th</sup> January, 2024. Copy of the letter from Ms. Samina Hamied is attached.

Details required to be disclosed under the SEBI Listing Regulations read with Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 have been provided in Annexure – A and B to this letter.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Encl: As above

**Annexure A**

<b>DIN</b>	10479707
<b>Name of Director</b>	Dr. Balram Bhargava
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Appointment of Dr. Balram Bhargava, as an additional and independent director of the Company for a period of 5 years w.e.f. 1 <sup>st</sup> April 2024 to 31 <sup>st</sup> March 2029 (both days inclusive).
<b>Date of appointment / <del>cessation</del> (as applicable) &amp; term of appointment</b>	For period of 5 year commencing from 1 <sup>st</sup> April 2024 to 31 <sup>st</sup> March 2029 (both days inclusive).
<b>Brief Profile</b>	<p>Dr. Balram Bhargava is a global public health leader. Mission driven, results oriented health professional with more than 35 years of experience in leading medical research, strengthening health systems, health care innovation, managing pandemic preparedness and health care delivery in resource poor settings. As a global leader he has been in the forefront of south-south cooperation, promoting equity in access to health care, democratisation of scientific research and promoting public-private cooperation to bring new technologies and affordable innovative products into the health systems.</p> <p>He has led India's Department of Health Research as its Secretary and Director-General of the Indian Council of Medical Research. He is also a Professor of Cardiology at the All-India Institute of Medical Sciences, New Delhi and serves as the Executive Director for Stanford India Biodesign Centre, School of International Biodesign (SiB). An extensively published scientist with more than 300 articles in peer reviewed journals and editor-in-chief of the British Medical Journal Innovations and of the Indian Journal of Medical Research.</p> <p>His experience ranges from treating more than a quarter million patients, training and mentoring super specialised cardiologists to setting health care policies and standards and advising several Ministers of Health and Heads of Government. In recent years he has been at the forefront of managing several public health crises in India including covid-19 and brought Indian research in shaping contemporary global practice through vaccine development and describing role of plasma therapy. He has also received numerous international and national awards for his contributions to health and development and has delivered more than 50 orations across the globe. He has international experience of more than 6 years in the USA, Europe and the Middle East.</p>
<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	None
<b>Information as required pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018- 19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20<sup>th</sup> June 2018</b>	Dr. Balram Bhargava is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

**Annexure B**

<b>DIN</b>	00027923
<b>Name of Director</b>	Ms. Samina Hamied
<b>Reason for change</b>	Effective close of business hours of 31 <sup>st</sup> March, 2024, Ms. Samina Hamied has decided to step down from the position of Executive Vice Chairperson of the Company while continuing as a non-executive director liable to retire by rotation.
<b>Date of appointment / cessation &amp; term of appointment</b>	
<b>Brief profile</b>	<p>Samina Hamied is an alumna of the London School of Economics. She has worked with the leading global firm Goldman Sachs (UK &amp; US).</p> <p>Samina joined the Cipla leadership team in 2011 as Executive Director, and Global Head – Strategy, M&amp;A &amp; Cipla New Ventures. She has been instrumental in driving the Company’s transformation agenda; playing a key role in successfully incubating Cipla’s consumer health business and spearheading the company’s ambitious foray into the US market with strategic acquisitions. Samina has built a top-class leadership pipeline for the Company as it continues to spread its wings globally.</p> <p>In her previous role as the Executive Vice-Chairperson of Cipla, Samina focused on board and governance issues, in addition to furthering Cipla’s strategic priorities through key global partnerships, corporate culture, hiring the right talent, and public advocacy. Samina also chaired the Inclusion &amp; Diversity Council at Cipla.</p> <p>Recognised as the third generation of the founding family, Samina has been feted for her diverse work experience and business knowledge. She was amongst Business Today’s ‘Most Powerful Women in Business’ in 2017 &amp; 2022. In 2018, Forbes featured Samina in the ‘Top 25 Emergent Women Business Leaders in Asia’. Fortune India named her amongst the ‘Most Powerful Women in Business for five consecutive years (2018-2022)’. She was awarded ‘Businesswoman of the Year’ at The Economic Times Awards for Corporate Excellence in 2021. Most recently, Samina was conferred the ‘EY Entrepreneur of the Year 2022’ in life sciences and healthcare category; and was named among the ‘Most Influential Women in Healthcare 2023’ by BW Healthcare World.</p>
<b>Disclosure of relationship between directors</b>	Ms. Samina Hamied is daughter of Mr. M. K. Hamied, Vice Chairman and niece of Dr. Y. K. Hamied, Chairman.
<b>Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018- 19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20th June 2018</b>	Ms. Samina Hamied is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

# Samina Hamied

---

Date: 25<sup>th</sup> January, 2024

To,

**The Board of Directors,**  
Cipla Limited,  
Cipla House, Peninsula Business Park,  
Ganpatrao Kadam Marg, Lower Parel,  
Mumbai, Maharashtra, 400013

**Sub: Step down as Executive Vice Chairperson of Cipla Limited (the "Company")**

Respected members of the Board,

I would like to inform you of my decision to step down as Executive Vice Chairperson of Cipla due to personal and family commitments. I will continue to serve as a Non-Executive Director of the Company. The effective date for this transition will be March 31, 2024 and I will work with the Board to ensure a smooth transition.

I would like to take the opportunity to thank Dr Y.K.Hamied and Mr M.K.Hamied for their unending support and for putting faith in me to lead the organization. A decade ago they believed that Cipla needed an engaged and active promoter from the next generation to steer and strengthen the Company as we built a world class leadership team, forayed into new geographies and incubated new businesses. Today as I step down from my executive position, I am proud to say that Cipla is strong and resilient and ready for the future.

Cipla continues to be professionally managed and remains steadfast on its future growth path as exemplified by its performance over the recent years.

It has truly been a privilege to have been a part of the growth and transformation of the Company over the last decade. This would not have been possible without your support and guidance and my heartfelt thanks for the same.

Your sincerely,



Samina Hamied  
DIN: 00027923